Ocular hypotensive efficacy and safety of brinzolamide ophthalmic suspension 1% added to travoprost ophthalmic solution 0.004% therapy in patients with open-angle glaucoma or ocular hypertension^*

References

• Heijl A, Leske MC, Bengtsson B, et al.; Early Manifest Glaucoma Trial Group. Reduction of IOP and glaucoma progression results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268–79
   Google Scholar
• Goldberg I, Cunha-Vaz J, Jakobsen J-E, et al. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma 2001;10:414–22
   Google Scholar
• Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:472–84
   PubMed Web of Science ®Google Scholar
• van der Valk R, Webers CAB, Schouten JS, et al., et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs. A meta-analysis of randomized clinical trials. Ophthalmology 2005;112:1177–85
   Google Scholar
• Sharif NA, Davis TL, Williams GW. [3H]AL-5848 ([3H]9beta-(+)-fluprostenol). Carboxylic acid of travoprost (AL-6221), a novel FP prostaglandin to study the pharmacology and autoradiographic localization of the FP receptor. J Pharm Pharmacol 1999;51: 685–94
   Google Scholar
• Davis TL, Sharif NA. Quantitative autoradiographic visualization and pharmacology of FP-prostaglandin receptors in human eyes using the novel phosphor-imaging technology. J Ocul Pharmacol Ther 1999;15:323–36
   PubMed Web of Science ®Google Scholar
• Hellberg MR, Sallee VL, McLaughlin MA, et al. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. J Ocul Pharmacol Ther 2001;17:421–32
   PubMed Web of Science ®Google Scholar
• Schachtschabel U, Lindsey JD, Weinreb RN. The mechanism of action of prostaglandins on uveoscleral outflow. Curr Opin Ophthalmol 2000;11:112–5
   PubMedGoogle Scholar
• Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study. A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701–13
   Google Scholar
• Wang YL, Toris CB, Zhan G, Yablonski ME. Effects of topical epinephrine on aqueous humor dynamics in the cat. Exp Eye Res 1999;68:439–45
   PubMed Web of Science ®Google Scholar
• Schenker HI, Yablonski ME, Podos SM, Linder L. Fluorophotometric study of epinephrine and timolol in human subjects. Arch Ophthalmol 1981;99:1212–6
   PubMed Web of Science ®Google Scholar
• Higginbotham EJ, Diestelhorst M, Pfeiffer N, et al. The efficacy and safety of unfixed and fixed combination of latanoprost and other antiglaucoma medications. Surv Ophthalmol 2002;47:S133–S140
   PubMed Web of Science ®Google Scholar
• Novack GD, O’Donnell MJ, Molloy DW. New glaucoma medications in the geriatric population: efficacy and safety. J Am Geriatr Soc 2002;50:956–62
   PubMed Web of Science ®Google Scholar
• Kirwan JF, Nightingale JA, Bunce C, Wormald R. Beta blockers for glaucoma and excess risk of airways obstruction: population based cohort study. Br Med J 2002;325:1396–7
   PubMed Web of Science ®Google Scholar
• DeSantis L. Preclinical overview of brinzolamide. Surv Ophthalmol 2000;44(Suppl 2):S119–S129
   PubMed Web of Science ®Google Scholar
• Silver LH. Dose–response evaluation of the ocular hypotensive effect of brinzolamide ophthalmic suspension (Azopt) [Brinzolamide dose–response study group]. Surv Ophthalmol 2000;44(Suppl 2):S147–S153
   PubMed Web of Science ®Google Scholar
• Silver LH. Clinical efficacy and safety of brinzolamide (Azopt), new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension [Brinzolamide primary therapy study group]. Am J Ophthalmol 1998;126:400–8
   PubMed Web of Science ®Google Scholar
• Barnebey H, Kwok SY. Patients’ acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting. Clin Ther 2000;22:1204–12
   PubMed Web of Science ®Google Scholar
• Silver LH, the Brinzolamide Comfort Study Group. Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. Surv Ophthalmol 2000;44:S141–S145
   Google Scholar
• Stewart WC, Day DG, Stewart JA, et al. Short-term ocular tolerability of dorzolamide 2% and brinzolamide1% vs placebo in primary open-angle glaucoma and ocular hypertension subjects. Eye 2004;18:905–10
   PubMed Web of Science ®Google Scholar
• Azoptâ summary of product characteristics. 2 June 2005
   Google Scholar
• Noecker RS, Dirks MS, Choplin NT, et al. A six month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 2003;135:55–63
   PubMed Web of Science ®Google Scholar
• Anon. Preferred practice pattern: primary open-angle glaucoma. American Academy of Ophthalmology; 2003. p. 19
   Google Scholar
• O’Connor DJ, Martone JF, Mead A. Additive intraocular pressure lowering effect of various medications with latanoprost. Am J Ophthalmol 2002;133:836–7
   Google Scholar
• Shoji N, Ogata H, Suyama H, et al. Intraocular pressure lowering effect of brinzolamide 1.0% as adjunctive therapy to latanoprost 0.005% in patients with open angle glaucoma or ocular hypertension: an uncontrolled, open-label study. Curr Med Res Opin 2005;21: 503–7
   Google Scholar
• The AGIS Investigators. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429–40
   Google Scholar
• Travatan® summary of product characteristics. 24 October 2003
   Google Scholar
• Sugrue MF. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Prog Retinal Eye Res 2000;19:87–112
   PubMed Web of Science ®Google Scholar